Combo-VAS: an integrated outcome for assessing the perception of allergen immunotherapy effectiveness in clinical practice.

Allergen Immunotherapy (AIT) is at present indicated for treating respiratory, food, and venom allergy.1 Usually, AIT lasts for some years, but its efficacy is longstanding. These aspects make AIT irreplaceable compared to conventional pharmacological medications. However, AIT presents some disadvantages, including very long duration, high cost, potential side effects, and low compliance, mainly concerning the sublingual route.2 In addition, another limitation of AIT is the lack of simple and reliable criteria of efficacy assessment both considering clinical or laboratory biomarkers.

https://ift.tt/2KFoQl0